Drugs / ALG-055009
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06959888 | Mar → May 2025 | — | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06191991 | Nov 2023 | — | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05090111 | Dec 2021 → Jun 2023 | metabolic dysfunction-associated steatohepatitis | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06342947 | Apr → Aug 2024 | metabolic dysfunction-associated steatohepatitis | Aligos Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-055009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06191991 ↗ |
| Route | Oral | “Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days” NCT05090111 ↗ |